Please use this identifier to cite or link to this item: https://hdl.handle.net/11147/10121
Title: A novel biomarker for drug resistance in chronic myeloid leukemia: MicroRNA-17
Authors: Baran, Yusuf
Fıratlıgil, Burcu
Kartal Yandım, Melis
Kiraz, Yağmur
Kozanoğlu, İlknur
Özdoğu, Hakan
Ünal, Ali
Publisher: Elsevier Ltd.
Abstract: miRNAs are single stranded small RNA molecules (20–22 nt), which do not have ability to code for proteins. These types of RNAs play significant roles on gene regulation through inhibition of their target genes. In animals, most of miRNAs show their translational inhibitor effect on target mRNAs by semi-complementation to 3’UTR sequences of mRNAs and deadenylation that cause degradation of these mRNAs. The importance of miRNAs is increasing in cancer diagnosis and treatment since they are one of the major regulators of genes such as oncogenes, tumor suppressor genes. miR-17 is an oncogenic miRNA that suppress the activation of tumor suppressor genes like CDKN1A, p21 and E2F1. Based on previous information, we aimed to determine the correlation between expression levels of miR-17 microRNA in newly diagnosed, tyrosine kinase inhibitors treated and drug resistant CML patients.
Description: 5th International Eurasian Hematology Congress
URI: https://doi.org/10.1016/S0145-2126(14)70122-5
https://hdl.handle.net/11147/10121
ISSN: 0145-2126
Appears in Collections:Molecular Biology and Genetics / Moleküler Biyoloji ve Genetik
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Files in This Item:
File SizeFormat 
1-s2.0-S0145212614701225-main.pdf75.89 kBAdobe PDFView/Open
Show full item record



CORE Recommender

Page view(s)

298
checked on Dec 2, 2024

Download(s)

180
checked on Dec 2, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.